ReviewJournal of clinical oncology : official journal of the American Society of Clinical Oncology2018
New Agents, Emerging Late Effects, and the Development of Precision Survivorship.
Review in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 53 citations in OpenAlex.
- Prevalence and Risk Factors for Financial Toxicity Among Sarcoma Patients During and Following Treatment Across the Lifespan.Cancer reports (Hoboken, N.J.) · 2026Article
- Gonadal and growth impairment in childhood cancer survivors' cohort.Discover oncology · 2026Article
- Unraveling the genetic blueprint of doxorubicin-induced cardiotoxicity through systems genetics approaches.Cardio-oncology (London, England) · 2025Article
- Assessing Pulmonary Function in Children and Adolescents After Cancer Treatment: Protocol for a Multicenter Cohort Study (Swiss Childhood Cancer Survivor Study FollowUp-Pulmo).JMIR research protocols · 2025Observational
- Impact of Volumetric Dosimetry on the Projected Cost of Radiation-Related Late Effects Screening After Childhood Cancer: A Real-World Cohort Analysis.The oncologist · 2023Article
- Gonadal Function in Female Adolescent and Young Adult Survivors of Childhood Cancer.Cancer research and treatment · 2023Article
- Informatics tools to implement late cardiovascular risk prediction modeling for population management of high-risk childhood cancer survivors.Pediatric blood & cancer · 2023Article
- Data Science and Precision Oncology Nursing: Creating an Analytic Ecosystem to Support Personalized Supportive Care across the Trajectory of Illness.Seminars in oncology nursing · 2023Article
- Hope in the era of precision oncology: a qualitative study of informal caregivers' experiences.BMJ open · 2023Article
- Neuroimaging based biotypes for precision diagnosis and prognosis in cancer-related cognitive impairment.Frontiers in medicine · 2023Review
- Mitigating, monitoring, and managing long-term chemotherapy- and radiation-induced cardiac toxicity.Hematology. American Society of Hematology. Education Program · 2022Article
- Article
- The Impact of Exercise on Cardiotoxicity in Pediatric and Adolescent Cancer Survivors: A Scoping Review.Current oncology (Toronto, Ont.) · 2022Article
- Leveraging Clinical Trial Populations and Data from the Children's Oncology Group for Cancer Survivorship Research.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022Article
- Validity of Administrative Data for Identifying Birth-Related Outcomes with the End Date of Pregnancy in a Japanese University Hospital.International journal of environmental research and public health · 2022Article
- Brazilian Position Statement on the Use Of Multimodality Imaging in Cardio-Oncology - 2021.Arquivos brasileiros de cardiologia · 2021Article
- Review
- Genetic factors in treatment-related cardiovascular complications in survivors of childhood acute lymphoblastic leukemia.Pharmacogenomics · 2021Article
- Immunotherapy use outside clinical trial populations: never say never?Annals of oncology : official journal of the European Society for Medical Oncology · 2021Review
- Patterns of surveillance for late effects of BCR-ABL tyrosine kinase inhibitors in survivors of pediatric Philadelphia chromosome positive leukemias.BMC cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Incremental improvements in the treatment of children and adolescents with cancer have led to 5-year survival rates reaching nearly 85%. In the past decade, impressive progress has been made in understanding the biology of many pediatric cancers. With that understanding, multiple new agents have become available that offer the promise of more-effective and less-toxic treatment. These include agents that target various cell surface antigens and engage the adaptive immune system, as well as those that interfere with key signaling pathways involved in tumor development and growth. For local control, surgery and radiation techniques also have evolved, becoming less invasive or featuring new techniques and particles that more precisely target the tumor and limit the dose to normal tissue. Nevertheless, targeted agents, like conventional chemotherapy, radiotherapy, and surgery, may have off-target effects and deserve long-term follow-up of their safety and efficacy. These include injury to the endocrine, cardiovascular, and immunologic systems. New radiation and surgical techniques that theoretically reduce morbidity and improve long-term quality of life must also be validated with actual patient outcomes. Finally, with advances in genomics, information on host susceptibility to late effects is beginning to emerge. Such knowledge, coupled with improved metrics that better describe the spectrum of potential late effects across the entire lifespan, can lead to the development of decision models that project the potential long-term health outcomes associated with various treatment and follow-up strategies. These developments will help extend the current focus on precision medicine to precision survivorship, where clinicians, patients, and families will have a better grasp of the potential risks, benefits, and tradeoffs associated with the growing number of cancer treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.